精密医学——不仅仅是肿瘤了

This is the question AbbVie drug researchers and developers want to answer, said Ian McCaffery, Ph.D., Vice President of Precision Medicine.  

Precision medicine – or “PMed” as it’s called around AbbVie’s labs and hallways – is spearheaded by McCaffery who joined AbbVie in March 2020 and brought with him 20 years of precision medicine experience with most of that time in the biotech industry. At AbbVie, his team of almost 200 researchers spans from the west coast to the east coast to Europe. 

“I remember when patients were diagnosed with cancer – it was considered one disease,” McCaffery said. “Then, advancements like precision medicine helped researchers understand the complexity of the disease, and how a person’s genetics change the disease and change how to treat that disease. We're learning that like cancer, immune-related diseases are not uniform and have different drivers. We are working to identify and target those drivers.”

在过去的几十年中,精密医学革命如何诊断和治疗癌症患者。通过裁剪治疗特定疾病的司机,考虑一个人的基因,环境和生活方式,研究人员可以针对正确的患者正确的药物在正确的时间。当科学家们找到工作,他们认为,接下来是什么?如果可以利用精密医学帮助对抗疾病除了癌症吗?

这是AbbVie药品研究人员和开发人员想要回答的问题,博士,副总裁Ian McCaffery说精密医学。

精密医学——或“点”叫做AbbVie的实验室和走廊——McCaffery牵头在2020年3月加入AbbVie,带来了20年的精密医学经验与生物技术行业的大部分时间。AbbVie,他将近200的研究团队跨越从西海岸到东海岸去欧洲。

“我记得当病人被诊断出患有癌症,它被认为是一种疾病,”McCaffery说。“然后,进步就像精密医学帮助研究人员了解该疾病的复杂性,以及一个人的基因改变的疾病和如何治疗疾病。我们学习,像癌症、免疫相关疾病和有不同的司机也不一致。我们正在努力确定和目标这些司机。”

“This means that precision medicine takes a village. It requires clinical and translational scientists working closely with colleagues from other groups in R&D to bring all the necessary expertise to generate and interpret molecular information. While this complexity can seem daunting, AbbVie has broad and deep expertise across the organization.”

This expertise comes from cutting-edge technologies used to identify predictive markers that build upon our understanding of molecular drivers. For some diseases, especially where phenotypic data are hard to quantify, AbbVie researchers are incorporating digital technologies including sensors, wearables, and other technologies to help identify which patients would benefit most from a treatment, McCaffrey said.

找到合适的患者为一个特定的治疗,AbbVie研究者使用预测生物标志物和最终的伴侣诊断化验测试用来帮助病人匹配特定的药物或疗法。但这一切始于发展中深入了解每一个疾病的司机,突变,导致肿瘤的生长。“发展中深、分子的理解疾病是高度复杂的,需要整个公司的技术,“McCaffery说。

“这意味着精密医学需要一个村庄。它需要临床和转化的科学家与其他组的同事密切合作研发将所有必要的专业知识分子信息生成和解释。虽然这似乎令人生畏的复杂性,AbbVie跨组织的广泛而深入的专业知识。”

这个专业知识来自尖端技术用于识别预测标记建立我们理解分子的司机。对于某些疾病,特别是在表型数据很难量化,AbbVie研究者将数字技术包括传感器、衣物,和其他技术来帮助确定哪些患者可能从治疗中获益,麦说。

Precision medicine, which already plays an important role in our work in R&D, will play an even bigger role in the coming years, said Neil Gallagher, M.D., Ph.D., Chief Medical Officer and Vice President of Development.

“We want to be aspirational and do something big that will help address a huge unmet need,” Gallagher said. “In the past two decades we have learned so much in oncology about the molecular biology of cancer and that has led to better treatments for patients. We want to do the same for immunology. We want to change the way we develop new immunology drugs and make them more effective and precise for each patient. If we can bring a new medicine that really makes a difference for, say 10% of ulcerative colitis patients, that would have a significant positive impact for those patients.”

Ulcerative colitis is a chronic disease of the large intestine, in which the lining of the colon becomes inflamed and develops tiny open sores, or ulcers. It causes painful symptoms that can be severe and include diarrhea, abdominal pain and cramping, rectal pain and bleeding, fatigue, and urgent bowel movements. The cause of the disease is unknown, but research does point to a patient’s genes and environment as possible factors, which aligns to precision medicine.

Ulcerative colitis currently lacks a non-invasive disease monitoring tool to measure and predict treatment outcomes, so an AbbVie team is exploring opportunities to work with inflammatory bowel disease experts across the country to conduct a digital biomarker study and help address this unmet need.

“These digital analyses could indicate disease or mechanistic activity in patients or be associated with treatment response,” Gallagher said. “By using these approaches, we hope to not only accelerate medicine development but also someday put these tools in the hands of patients and doctors to help guide treatment decisions.”

研究人员也使用先进的机器学习和人工智能照亮从高度复杂和多模式数据预测的关系,包括临床、分子和数字数据。这些分析工具是给团队一看数字病理水平的疾病。

精密医学,已经在研发工作中扮演着重要的角色,发挥更大的作用在未来几年,尼尔·加拉格尔说,医学博士博士,首席医疗官的发展和副总统。狗万正网地址

“我们想要的,做大,这将有助于解决一个巨大的未满足的需求,”加拉格尔说。“在过去的二十年里我们学到了很多在肿瘤分子生物学的癌症,导致更好的治疗病人。我们想做同样的免疫学。我们想改变我们开发新的免疫学药物和为每个病人使他们更有效和准确。如果我们能带来非常重要的新药,说10%的溃疡性结肠炎患者,这将对那些病人有显著积极影响。”

溃疡性结肠炎是一种慢性疾病的大肠,结肠内壁变得红肿和发展小溃疡,或溃疡。它会导致痛苦的症状,可以包括严重的腹泻,腹痛和抽筋、直肠疼痛和出血,疲劳,和急迫的排便。疾病的原因尚不清楚,但研究并指出病人的基因和环境因素,将精密医学。

溃疡性结肠炎目前缺乏一个非侵入性疾病监控工具来测量和预测治疗结果,所以一个AbbVie团队正在探索的机会与炎症性肠病专家工作在全国各地进行数字生物标志物研究和帮助解决这个未满足的需求。

“这些数字分析表明疾病患者或机械的活动或可能与治疗反应相关,”加拉格尔说。“通过使用这些方法,我们希望不仅促进医学发展,也总有一天把这些工具放在病人和医生的手帮助指导治疗决策。”狗万正网地址

Even AbbVie’s Discovery group, which drives early science and early pipeline work, is looking at how precision medicine can help patients beyond oncology and immunology. For example, neuroscience teams are also using imaging and biomarkers to study the most promising areas of disease biology to help develop strategies that directly target disease pathology to potentially treat diseases like Alzheimer’s and Parkinson’s.

“When someone has a fever, doctors want to know the cause,” Hudson said. “They don’t stop at treating the fever. That is where medicine is headed in the next decade. There is not one drug for breast cancer or one drug for lupus. We want to know the cause and the pathology of that disease that is specific for each patient. In the future, we hope that understanding will lead to more targeted and effective medicines for patients.”

汤姆·哈德逊,医学博士AbbVie研发的高级副总裁和首席科学官设想“精密医学对于每一个项目。”

甚至AbbVie发现集团推动早期科学和早期管道工作,看着精密医学如何帮助病人除了肿瘤学和免疫学。例如,神经科学团队也使用成像和生物标志物研究疾病的最有前途的领域直接帮助发展策略目标疾病病理生物学可能治疗阿尔茨海默氏症和帕金森氏症等疾病。

“当有人发烧,医生想知道原因,“哈德逊说。“他们不停止治疗发烧。这就是医学是在下一个十年。没有一种药物对乳腺癌或治疗狼疮的药物之一。我们想知道原因和特定疾病的病理学为每一个病人。在未来,我们希望了解会导致更有针对性和有效的药物对病人。”